Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. Show more
Location: 47 Hulfish Street, Princeton, NJ, 08542, United States | Website: https://amicusrx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
2.42B
52 Wk Range
$5.51 - $12.65
Previous Close
$7.85
Open
$7.83
Volume
3,879,611
Day Range
$7.81 - $8.03
Enterprise Value
2.64B
Cash
231M
Avg Qtr Burn
-11.41M
Insider Ownership
0.71%
Institutional Own.
-
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Galafold (migalastat) Details Fabry disease | Approved Quarterly sales | |
Approved Quarterly sales | ||
AT-GTX-502 Details Batten Disease | Failed Discontinued | |
AT-GTX-501 Details Batten Disease | Failed Discontinued |